TS23

Phase 2Small molecule

TTranslational Sciences, Inc.

TS23 is one of 66 small molecule programs targeting Stroke. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

StrokeActive, not recruiting

Pulmonary EmbolismActive, not recruiting

StrokePhase 2

Active, not recruiting

Pulmonary EmbolismPhase 2

Active, not recruiting

Competition

Competitive Landscape

461 competitors in Stroke

#DrugCompanyPhaseTrials

Activase

Roche

Preclinical

19 2

Savella

AbbVie

Preclinical

1 3

Repatha

Amgen

Preclinical

—4

Botox

RRevance Therapeutics, Inc.

Preclinical

2 5

TS23

TTranslational Sciences, Inc.

Phase 2

1 6

Periactin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 7

Zantac 150

CChattem

Preclinical

1 8

Direct Anticoagulant

Bayer

Preclinical

3 9

Anticoagulants

Sanofi

Preclinical

1 10

Carbidopa-Levodopa

Neurocrine Biosciences

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Pulmonary Embolism

NCT05408546

Q4 2027

Phase 2Recruiting

Stroke

NCT05948566

Clinical

Trials by Indication[1]

Stroke1 trial

Strategy for Improving Stroke Treatment Response

Recruiting·TTranslational Sciences, Inc.·Phase 2·NCT05948566·300 enrolled

Biomarker1 trial

Study of Safety and Biomarker Efficacy of TS23 in Healthy Volunteer

Unknown status·TTranslational Sciences, Inc.·Phase 1·NCT03001544·24 enrolled

Pulmonary Embolism1 trial

Evaluation of the Safety and Thrombolytic Effects of Ascending Doses of TS23 in Subjects With Intermediate-Risk (Sub-Massive) Acute Pulmonary Embolism

Active, not recruiting·TTranslational Sciences, Inc.·Phase 2·NCT05408546·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for TS23. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TS23 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TS23. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Translational Sciences, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTranslational Sciences, Inc.

TS23

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Trials by Indication[1]

Stroke1 trial

Biomarker1 trial

Pulmonary Embolism1 trial

References

Drug Info

Quick Facts

Related News